Analyzing Craneware (OTCMKTS:CRWRF) & Forian (NASDAQ:FORA)

Forian (NASDAQ:FORA) and Craneware (OTCMKTS:CRWRF) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Forian and Craneware, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forian	0	0	1	0	3.00
Craneware	0	0	0	0	0.00

Forian currently has a consensus price target of $5.00, indicating a potential upside of 146.31%. Given Forian’s stronger consensus rating and higher possible upside, research analysts clearly believe Forian is more favorable than Craneware.

Valuation and Earnings

This table compares Forian and Craneware”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forian	$19.71 million	3.19	-$2.79 million	($0.09)	-22.56
Craneware	N/A	N/A	N/A	$0.32	87.70

Craneware has lower revenue, but higher earnings than Forian. Forian is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

19.3% of Forian shares are owned by institutional investors. Comparatively, 48.2% of Craneware shares are owned by institutional investors. 31.3% of Forian shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Forian and Craneware’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Forian	N/A	N/A	N/A
Craneware	N/A	N/A	N/A

Summary

Forian beats Craneware on 5 of the 8 factors compared between the two stocks.

About Forian

Forian Inc. provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions. The company’s subscription and services-based solutions cover the life sciences, pharma services, and healthcare payer and provider industries. Forian Inc. was founded in 2020 and is headquartered in Newtown, Pennsylvania.

About Craneware

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers Trisus Decision Support; Trisus Labor Productivity; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, it offers appeal, professional, and pharmacy professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.